Validation Requirements for Disinfection Efficacy - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Validation Requirements for Disinfection Efficacy


Pharmaceutical Technology
Volume 37, Issue 1, pp. 35

RELATED ARTICLES

More in GMPs/Validation

Q Is the periodic re-evaluation of disinfectant efficacy useful in any way? I have been asked to repeat these studies even though they have been done in the past. There's been no change to the materials or methods since that time.


John S. Kent
A In the pharmaceutical manufacturing industry, operating under GMPs, the periodic revalidation of disinfection efficacy is not scientifically justified or required provided the disinfectant used remains the same, the dilution of the disinfectant is still the same, the challenge organisms (including environmental isolates) are still the same, the manufacturing environment surfaces are still the same and the vendor for the disinfectant is still the same. To my knowledge, only when one of these five elements regarding cleanroom disinfection is changed are you required to repeat the validation of disinfection efficacy testing. Periodic revalidation of a disinfectant serves no useful scientific purpose and I do not know of an FDA regulation that states that one must periodically revalidate disinfectants. Be sure to execute the disinfection efficacy validation properly and have complete documentation.

John S. Kent, PhD
Principal, Pharmaceutical Development Consulting
San Mateo, CA (USA) 94403

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here